share_log

VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

VERU 诉讼警报:Levi & Korsinsky 向 Veru Inc. 投资者通报了集体诉讼和即将到来的截止日期
PR Newswire ·  2023/01/26 05:56

NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit.

纽约2023年1月26日 /PRNewswire/ — Levi & Korsinsky, LLP 通知投资者 Veru Inc. 集体诉讼证券诉讼的(“Veru” 或 “公司”)(纳斯达克股票代码:VERU)。

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Veru investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive. Follow the link below to get more information and be contacted by a member of our team:

类定义: 该诉讼旨在代表因涉嫌证券欺诈而受到不利影响的Veru投资者追回损失。该诉讼是代表所有在两者之间购买或以其他方式收购Veru Inc.普通股的投资者提起的 2022年5月11日2022年11月9日,包括。点击以下链接获取更多信息,我们的团队成员将与您联系:

VERU investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

真的投资者也可以联系 Joseph E. Levi,Esq. 通过电子邮件发送至 [email protected] 或致电 (212) 363-7500。

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.

案例详情: 提起的申诉指控被告作了虚假陈述和/或隐瞒了以下事实:1) 公司隐瞒了有关sabizabulin第三阶段试验数据以及该公司与美国食品药品监督管理局互动的重大不利事实;2) 被告误导了Veru的股东,使他们相信sabizabulin第三阶段试验的数据足以支持紧急使用授权(“EUA”),甚至无需提交新药申请任何进一步的研究;以及 3) 公司的文件掩盖了真正的风险Veru在获得其EUA请求的批准时面临着这个问题。

WHAT'S NEXT? If you suffered a loss in Veru during the relevant time frame, you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

下一步是什么? 如果您在相关时间范围内在 Veru 中遭受了损失,则必须等到 2023年2月6日要求法院任命你为首席原告。您无需担任首席原告即可分担任何追回款项。

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

对你来说不用花钱: 如果您是集体成员,则可能有权在不支付任何自付费用或费用的情况下获得赔偿。 没有参与的费用或义务。

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

为什么是李维和科尔辛斯基: 在过去的20年中,Levi & Korsinsky的团队为受侵害的股东筹集了数亿美元,并在赢得高风险案件方面创造了良好的记录。我们公司在复杂的证券诉讼中代表投资者拥有丰富的专业知识,并拥有一支由70多名员工组成的团队为我们的客户提供服务。Levi & Korsinsky连续七年在ISS证券集体诉讼服务公司的50强报告中被评为美国顶级证券诉讼公司之一 美国

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

联系人:
Levi & Korsinsky,LLP
Joseph E. Levi,Esq.
Ed Korsinsky,Esq。
百老汇 55 号,10 楼
纽约,纽约 10006
[电子邮件保护]
电话:(212) 363-7500
传真:(212) 363-7171

SOURCE Levi & Korsinsky, LLP

来源 Levi & Korsinsky,LLP

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发